Delving into the Latest Updates on EnhancedBio, Inc. with Synapse

概览

疾病领域	数量

肿瘤	9
内分泌与代谢疾病	2
血液及淋巴系统疾病	1

排名前五的药物类型	数量

siRNA	4
小分子化药	3
蛋白水解靶向嵌合体（PROTAC）	2

排名前五的靶点	数量

ERα(雌激素受体α)	2
BTK(酪氨酸蛋白激酶BTK)	1
PMVK	1
HPV E6 x HPV E7	1
SERT(5-羟色胺转运体)	1

关联

10

项与 EnhancedBio, Inc. 相关的药物

Borestrant

靶点

ERα

作用机制

ESR1降解剂

在研机构

EnhancedBio, Inc.初创企业 [+1]

原研机构

EnhancedBio, Inc.初创企业

在研适应症

ER阳性/HER2阴性乳腺癌

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

BTK-PROTAC(EnhancedBio, Inc.)

靶点

BTK

作用机制

BTK抑制剂

在研机构

EnhancedBio, Inc.初创企业

原研机构

EnhancedBio, Inc.初创企业

在研适应症

血液肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Corpitenib

靶点-

作用机制-

在研机构

EnhancedBio, Inc.初创企业

原研机构

EnhancedBio, Inc.初创企业

在研适应症

转移性结直肠癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 EnhancedBio, Inc. 相关的临床结果

登录后查看更多信息

0 项与 EnhancedBio, Inc. 相关的专利（医药）

登录后查看更多信息

4

项与 EnhancedBio, Inc. 相关的文献（医药）

2023-04-04·Cancer Research

Abstract 3779: Evaluation of anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6 and E7 combined with cisplatin in xenograft model of cervical cancer

作者: Lee, Ji-young ; Lee, Shin-Wha ; Kim, Yong-Man ; Kang, Sung Wan ; Kim, Hyejeong ; Kang, Ok Ju ; Kim, Yisak

AbstractBackground: High-risk human papillomavirus (HPV) type 16 is the major etiological agent found in more than 60% of patients with cervical cancer and associated with cancer development and progression. Persistent expression HPV E6 and E7 oncoproteins are essential for the initiation and maintenance of cervical cancer. The therapeutic approaches targeting HPV E6 and E7 have been proved to be highly efficient in killing malignant cells. The suppression of HPV 16 E6/E7 expression by the short interfering RNA (siRNA) was more effective in combination therapy with cisplatin (CDDP) for cervical cancer. ENB101-LNP is an ionizable lipid nanoparticles (LNPs) encapsulating siRNA against E6/E7 of HPV 16 for delivery to the tumor cells.Methods: To investigate the anticancer efficacy and mechanism of ENB101-LNP combined with cisplatin in cervical cancer; the xenograft model was generated by the injection of CaSki cells subcutaneously into BALB/c nude mice. Mice were randomly divided into six groups: 1) blank control; 2) 1mg/kg ENB101-LNP; 3) 3mg/kg ENB101-LNP; 4) CDDP; 5) 1mg/kg ENB101-LNP-CDDP; 6) 3mg/kg ENB101-LNP-CDDP. ENB101-LNP was treated with intravenous injection three times weekly for 3 weeks and CDDP was treated with IP injection once a week for 3 weeks. Tumor growth curves were plotted to calculate the tumor inhibition rate. Mice were sacrificed one week after the last treatment and the tumor tissues were investigated using histopathology, immunohistochemical staining and western blotting.Results: Compared with the control and the other treatment groups, the tumor growth was significantly inhibited (P < 0.05). The tumor inhibition rate was 29.7% in 1mg/kg ENB101-LNP group, 29.6% in 3mg/kg ENB101-LNP group, 34.0% in CDDP group, 47.0% in 1mg/kg ENB101-LNP-CDDP group. At the dose of 3mg ENB101-LNP/kg combined with CDDP exhibited superior antitumor efficacy, the tumor inhibition rate was 68.8%. The successful ENB101-LNP mediated knockdown (with up to 80%) of HPV16 E6/E7 in tumors of both 1mg/kg and 3mg/kg groups was confirmed by RT-PCR. The ENB101-LNP increased p53 and p21 expression in tumors compared to control and CDDP alone groups and combination treatment with CDDP showed decreased expression of PD-L1 expression compared to CDDP alone group. The treatment of ENB101-LNP and combination with CDDP showed significant increase in apoptotic cells compared to control and single-agent groups respectively.Conclusions: The ENB101-LNP inhibiting E6 and E7 of HPV 16 in combination with CDDP showed promising anticancer activity in the cervical cancer cells xenograft mouse model.Citation Format: Sung Wan Kang, Shin-Wha Lee, Ji-young Lee, Ok Ju Kang, Hyejeong Kim, Yisak Kim, Yong-Man Kim. Evaluation of anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6 and E7 combined with cisplatin in xenograft model of cervical cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3779.

Pharmaceuticals3区 · 医学

Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies

3区 · 医学

ArticleOA

作者: Rajasekaran, Nirmal ; Guo, Shanchun ; Kang, Borui ; Hossain, Ahamed ; Liu, Jiawang ; Jung, Hunsoon ; Wang, Guangdi ; Kim, Hongjoong ; Zhang, Changde

Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to have high plasma protein binding in human and animal plasma, and low intestinal mucosal permeability. ZB716 had high clearance in hepatocytes of all species tested. ZB716 was metabolized primarily by CYP2D6 and CYP3A. In human liver microsomes, ZB716 demonstrated relatively low inhibition of CYP1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 (when testosterone was used as the substrate), and no inhibition of CYP2B6 and 3A4 (when midazolam was used as the substrate). In assays for enzyme activity, ZB716 induced CYP1A2, 2B6, and 3A4 in a concentration-dependent manner. Single-dose and repeated-dose pharmacokinetic studies in rats and dogs showed oral bioavailability, dose-proportional drug exposure, and drug accumulation as measured by maximum concentration and area under the concentration–time curve (AUC).

Frontiers in Oncology

Corrigendum: Dysregulation of miR-375/AEG-1 Axis by Human Papillomavirus 16/18-E6/E7 Promotes Cellular Proliferation, Migration, and Invasion in Cervical Cancer

作者: Shin, Young Kee ; Jung, Hun Soon ; Jayamohan, Sridharan ; Rajasekaran, Nirmal ; Arockiam, Antony Joseph Velanganni ; Kannan, Maheshkumar ; Moorthy, Rajesh Kannan

[This corrects the article DOI: 10.3389/fonc.2019.00847.].

100 项与 EnhancedBio, Inc. 相关的药物交易

登录后查看更多信息

100 项与 EnhancedBio, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月17日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

8

1

临床2期

其他

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Borestrant ( ERα )	ER阳性/HER2阴性乳腺癌更多	临床2期
Mevisiran	胰腺腺泡癌更多	临床前
Carvisiran	头颈部肿瘤更多	临床前
Corpitenib	转移性结直肠癌更多	临床前
ER-PROTAC(EnhancedBio, Inc.) ( ERα )	ER阳性/HER2阴性乳腺癌更多	临床前